Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy
Research output: Contribution to journal › Journal article › Research › peer-review
A 33-year-old patient suffered from recurring Beh,cet's colitis despite treatment with corticosteroids and later cyclosporin. The patient was then successfully shifted from cyclosporin, a T-cell specific immunosuppressant, to fusidic acid treatment (500 mg t.i.d.). During fusidic acid treatment, he went into complete remission, and his prednisolone dose could be reduced from 30 to 5 mg/day. The case report substantiates recent in vitro data indicating that fusidic acid has a similar effect on T-cell function as cyclosporin. It is suggested that the effect of fusidic acid in other chronic immunoinflammatory diseases should be examined.
Original language | English |
---|---|
Journal | Danish Medical Bulletin (Print) |
Volume | 38 |
Issue number | 3 |
Pages (from-to) | 284 |
ISSN | 0907-8916 |
Publication status | Published - Jun 1991 |
- Adult, Behcet Syndrome/complications, Colitis/complications, Fusidic Acid/therapeutic use, Humans, Immunosuppressive Agents/therapeutic use, Male, T-Lymphocytes/drug effects
Research areas
ID: 219531521